Page last updated: 2024-12-11
adrogolide hydrochloride
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
adrogolide hydrochloride: the diacetyl prodrug of A-86929; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6918298 |
CHEMBL ID | 2146092 |
SCHEMBL ID | 1229151 |
MeSH ID | M0577649 |
Synonyms (21)
Synonym |
---|
das-431 |
abt-431 |
a-93431.1 |
adrogolide hydrochloride |
adrogolide hydrochloride (usan) |
D02775 |
abt 431 |
das 431 |
unii-69mg3oza0h |
adrogolide hydrochloride [usan] |
adrogolide hcl |
(5ar,11bs)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo(f)thieno(2,3-c)quinoline-9,10-diol diacetate (ester), hydrochloride |
a 93431.1 |
benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride, (5ar-trans)- |
(5ar,11bs)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo(f)thieno(2,3-c)quinoline-9,10-diol, diacetate (ester), hydrochloride |
69mg3oza0h , |
CHEMBL2146092 |
(5ar,11bs)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3-c]quinoline-9,10-diol diacetate (ester), hydrochloride |
SCHEMBL1229151 |
166591-11-3 (hcl) |
AKOS040750152 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Following intratracheal instillation of the drug solution, the lung bioavailability was found to be approximately 75% in dogs." | ( Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. Adjei, AL; Bertz, RJ; El-Shourbagy, T; Marsh, KC; Zheng, Y, 1999) | 0.3 |
" Adrogolide undergoes a high hepatic "first-pass" metabolism in man after oral dosing and, as a result, has a low oral bioavailability (approximately 4%)." | ( Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. Giardina, WJ; Williams, M, 2001) | 0.31 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Adrogolide improves behavioral disability and locomotor activity scores in MPTP-lesioned marmosets, a model of Parkinson's disease (PD), and shows no tolerance upon repeated dosing for 28 days." | ( Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. Giardina, WJ; Williams, M, 2001) | 0.31 |
"A 60% ethanol formulation of 50 mg/mL ABT-431 was used to prepare unit dosage forms containing 40 microL of formulation." | ( Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Adjei, AL; Bertz, RJ; Blanchard, JD; Farr, SJ; Gonda, I; Lee, RY; Lloyd, PM; Okikawa, J; Okumu, FW; Queirolo, A; Rubsamen, R; Woods, CM, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (46.15) | 18.2507 |
2000's | 7 (53.85) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.33) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 5 (38.46%) | 5.53% |
Reviews | 1 (7.69%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (53.85%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |